Skip to NavigationSkip to content

EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024 - ref #GB000048

EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024

Gastric cancer, also called stomach cancer, is a multifactorial disease that starts in the tissues lining the stomach. Gastric cancer usually begins in cells in the inner layer of the stomach and tends to develop slowly into the outer layer over many years. In the early stages of gastric cancer, the affected individuals exhibit symptoms such as indigestion and stomach discomfort that require little medical attention and therefore, most of the cases remain undetected at the initial stages of the disease. Gastric cancer typically affects elderly individuals, ages 55 years and older, and peaks in the seventh decade of life and is twice as common in men as in women.

In 2014, there were a total of 312,520 diagnosed incident cases of gastric cancer in the 8MM. GlobalData epidemiologists forecast that the diagnosed incident cases of gastric cancer in the 8MM will increase to 364,518 cases by 2024 at an Annual Growth Rate (AGR) of 1.66%. In the 8MM, urban China had the highest number of diagnosed incident cases (134,968 cases) in 2014, and is expected to grow to 177,015 cases by 2024 at a high AGR of 3.12%.

GlobalData epidemiologists’ forecast for gastric cancer is supported by at least 10 years of historical data obtained from international cancer organizations, country-specific government sources, and peer-reviewed studies. The forecast of incident gastric cancer cases were based on detailed age-specific and sex-specific trends in incidence in each of the 8MM. This forecast provides detailed case-segmentation of the gastric cancer patient pool for each country by age, sex, and stage at diagnosis. Additionally, GlobalData’s analysis provides diagnosed incident cases of GEJ cancer and segmentation of diagnosed gastric cancer incident cases by cellular type and HER2 status. The forecast is driven by a thorough analysis of historical data. The forecast methodology was also consistent across all the 8MM, thereby allowing for a meaningful comparison of the forecast diagnosed incident and five-year diagnosed prevalent cases of gastric cancer across the 8MM.


- The Gastric Cancer EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for gastric cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast of the diagnosed incident cases of gastric cancer, gastroesophageal junction cancer, gastric adenocarcinoma, and the five-year diagnosed prevalent cases of gastric cancer segmented by age and sex in these markets. In addition this report provides further segmentation of gastric cancer by stage at diagnosis, cellular type, and human epidermal growth factor receptor status.
- The gastric cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Gastric Cancer EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global gastric cancer market.
- Quantify patient populations in the global gastric cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for gastric cancer therapeutics in each of the markets covered.

Publisher: GlobalData
Publication date: October 2015

Price: £ 2,632.70

You need to agree to the Terms and Conditions before placing your order

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches